- Accueil >
- Publications >
- Phase II Trial of Bevacizumab in Combination With Temozolomide as First‐Line Treatment in Patients With Metastatic Uveal Melanoma
Phase II Trial of Bevacizumab in Combination With Temozolomide as First‐Line Treatment in Patients With Metastatic Uveal Melanoma
Auteurs
Sophie Piperno‐Neumann, Alhassane Diallo, Marie‐Christine Etienne‐Grimaldi, François‐Clément Bidard, Manuel Rodrigues, Corine Plancher, Pascale Mariani, Nathalie Cassoux, Didier Decaudin, Bernard Asselain, Vincent Servois
Résumé
Abstract
Lessons Learned
Trials dedicated to metastatic uveal melanoma are needed because of the poor prognosis of this rare cancer and because its biology is distinct from that of cutaneous melanoma. Agents targeting the MEK/ERK/MAP kinase pathways are being tested.
Background.
In experimental models, bevacizumab suppressed in vitro growth and in vivo hepatic metastasis of ocular melanoma cells. Additional preclinical data suggested a potential benefit when combining bevacizumab with dacarbazine.
Methods.
This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m2 on days 1–7 and 15–21) in 36 patients with metastatic uveal melanoma (MUM). The primary endpoint was the progression-free rate (PFR) at 6 months. Using a modified 2-step Fleming plan, at least 10 of 35 patients were required to support a predefined PFR at 6 months of 40%. Secondary objectives were progression-free survival (PFS), overall survival (OS), and safety; liver perfusion computed tomography (CT) for response imaging; and impact of VEGF-A gene polymorphisms on bevacizumab pharmacodynamics.
Results.
First- and second-step analyses revealed nonprogression at 6 months in 3 of 17 and 8 of 35 patients, respectively. Finally, the 6-month PFR was 23% (95% confidence interval [CI]: 10–39), with long-lasting stable disease in 5 patients (14%). Median PFS and OS were 12 weeks and 10 months, respectively. No unexpected toxicity occurred. Liver perfusion CT imaging was not useful in assessing tumor response, and VEGF-A gene polymorphisms were not correlated with toxicity or survival.
Conclusion.
In patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.
